Furthermore we assessed the role of the alkyl-lipid Ohmline, previously identified through its SK3/Orai1 complex inhibition properties [12], to modify the actions of anti-EGFR mAbs such as cetuximab and panitumumab currently used in colon cancer therapeutic. The gene discussed is EGFR; the disease is colonic neoplasm.